These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32557982)

  • 1. CAIXplatins: Highly Potent Platinum(IV) Prodrugs Selective Against Carbonic Anhydrase IX for the Treatment of Hypoxic Tumors.
    Cao Q; Zhou DJ; Pan ZY; Yang GG; Zhang H; Ji LN; Mao ZW
    Angew Chem Int Ed Engl; 2020 Oct; 59(42):18556-18562. PubMed ID: 32557982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
    Wang Z; Deng Z; Zhu G
    Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Carbonic Anhydrase IX (CAIX)-Anchored Rhenium(I) Photosensitizer Evokes Pyroptosis for Enhanced Anti-Tumor Immunity.
    Su X; Wang WJ; Cao Q; Zhang H; Liu B; Ling Y; Zhou X; Mao ZW
    Angew Chem Int Ed Engl; 2022 Feb; 61(8):e202115800. PubMed ID: 34842317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: Synthesis and Biological Evaluation.
    Anduran E; Aspatwar A; Parvathaneni NK; Suylen D; Bua S; Nocentini A; Parkkila S; Supuran CT; Dubois L; Lambin P; Winum JY
    Molecules; 2020 May; 25(10):. PubMed ID: 32443462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target.
    Drenckhan A; Freytag M; Supuran CT; Sauter G; Izbicki JR; Gros SJ
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1024-1033. PubMed ID: 29865880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.
    Ward C; Meehan J; Mullen P; Supuran C; Dixon JM; Thomas JS; Winum JY; Lambin P; Dubois L; Pavathaneni NK; Jarman EJ; Renshaw L; Um IH; Kay C; Harrison DJ; Kunkler IH; Langdon SP
    Oncotarget; 2015 Sep; 6(28):24856-70. PubMed ID: 26259239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.
    Marks IS; Gardeen SS; Kurdziel SJ; Nicolaou ST; Woods JE; Kularatne SA; Low PS
    Mol Pharm; 2018 Jun; 15(6):2289-2296. PubMed ID: 29715036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cobalt Bis(dicarbollide) Alkylsulfonamides: Potent and Highly Selective Inhibitors of Tumor Specific Carbonic Anhydrase IX.
    Grüner B; Kugler M; El Anwar S; Holub J; Nekvinda J; Bavol D; Růžičková Z; Pospíšilová K; Fábry M; Král V; Brynda J; Řezáčová P
    Chempluschem; 2021 Mar; 86(3):352-363. PubMed ID: 32955786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors.
    Faes S; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Datta D; Demartines N; Dormond O
    Oncotarget; 2016 Jun; 7(24):36666-36680. PubMed ID: 27153561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NIR phosphorescent cyclometalated platinum (II) complexes with CAIX targeted and nuclear penetration as potent anticancer theragnostic agents.
    Yang J; Chen DL; Wang PC; Yang B; Gao CZ
    Eur J Med Chem; 2022 Dec; 243():114702. PubMed ID: 36084533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
    Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
    Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
    Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
    Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity.
    Riemann A; Güttler A; Haupt V; Wichmann H; Reime S; Bache M; Vordermark D; Thews O
    Oncol Res; 2018 Mar; 26(2):191-200. PubMed ID: 28631600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.
    Lou Y; McDonald PC; Oloumi A; Chia S; Ostlund C; Ahmadi A; Kyle A; Auf dem Keller U; Leung S; Huntsman D; Clarke B; Sutherland BW; Waterhouse D; Bally M; Roskelley C; Overall CM; Minchinton A; Pacchiano F; Carta F; Scozzafava A; Touisni N; Winum JY; Supuran CT; Dedhar S
    Cancer Res; 2011 May; 71(9):3364-76. PubMed ID: 21415165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.
    Bryant JL; Gieling RG; Meredith SL; Allen TJ; Walker L; Telfer BA; Supuran CT; Williams KJ; White A
    Int J Cancer; 2018 Jan; 142(1):191-201. PubMed ID: 28905987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
    Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
    Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of carbonic anhydrase IX in the progression of malignant tumors - a potential therapeutic target?].
    Matolay O; Bádon SE; Balázs L; Juhász P; Csonka T; Méhes G
    Magy Onkol; 2021 Jun; 65(2):157-166. PubMed ID: 34081763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological evaluation of p-toluene sulphonylhydrazone as carbonic anhydrase IX inhibitors: An approach to fight hypoxia-induced tumors.
    Queen A; Khan P; Idrees D; Azam A; Hassan MI
    Int J Biol Macromol; 2018 Jan; 106():840-850. PubMed ID: 28830777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.
    Angeli A; Trallori E; Ferraroni M; Di Cesare Mannelli L; Ghelardini C; Supuran CT
    Eur J Med Chem; 2018 Sep; 157():1214-1222. PubMed ID: 30193219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-tail arylsulfone-based benzenesulfonamides differently match the hydrophobic and hydrophilic halves of human carbonic anhydrases active sites: Selective inhibitors for the tumor-associated hCA IX isoform.
    Ibrahim HS; Allam HA; Mahmoud WR; Bonardi A; Nocentini A; Gratteri P; Ibrahim ES; Abdel-Aziz HA; Supuran CT
    Eur J Med Chem; 2018 May; 152():1-9. PubMed ID: 29684705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.